Patients with sickle cell disease on vorinostat
| Patient . | Age, y . | Gender . | Baseline Hb, g/dL . | End-of-study Hb, g/dL . | Baseline HbF% . | Highest HbF% . | Grade 3/4 toxicity* . |
|---|---|---|---|---|---|---|---|
| 1 | 44 | M | 5.9 | 7.5 | 1.5 | 4.6 | Pain, headache |
| 2 | 43 | F | 5.7 | 5.3 | 13.8 | 12.8 | None |
| 3 | 37 | F | 8 | 8.9 | 5.6 | 6 | Pain |
| 4 | 31 | F | 7 | 7.5 | 9.2 | 10 | Pain |
| 5 | 21 | M | 8 | 8 | 16.55 | 20.5 | Pain |
| Patient . | Age, y . | Gender . | Baseline Hb, g/dL . | End-of-study Hb, g/dL . | Baseline HbF% . | Highest HbF% . | Grade 3/4 toxicity* . |
|---|---|---|---|---|---|---|---|
| 1 | 44 | M | 5.9 | 7.5 | 1.5 | 4.6 | Pain, headache |
| 2 | 43 | F | 5.7 | 5.3 | 13.8 | 12.8 | None |
| 3 | 37 | F | 8 | 8.9 | 5.6 | 6 | Pain |
| 4 | 31 | F | 7 | 7.5 | 9.2 | 10 | Pain |
| 5 | 21 | M | 8 | 8 | 16.55 | 20.5 | Pain |
All patients had HbSS genotype and all toxicities resolved completely.
Hb, hemoglobin.
Toxicity was graded based on Common Terminology Criteria for Adverse Events, version 4.0.